NCT Number: NCT00865033
A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion criteria
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Treatment and study plan
Glucophage 1000 mg
DrugPrimary outcomes
-
Bioequivalence according to US FDA guidelines
Time frame: 9 days
Sponsors and collaborators
Lead sponsor
Sandoz
Industry
Registry information
Official study title
A Relative Bioavailability Study of Metformin HCL 1000 mg Tablets Under Fasting Conditions
Important dates
- Study start
- 2005
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Mar 19, 2009
- Registry last updated
- Mar 29, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D
NCT07005362
Artificial Intelegence, Behavior
Aurora, Colorado, United States
View Trial DetailsA Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
Body Weight, Body Weight Changes
Daytona Beach, Florida, United States
View Trial DetailsPreventing T2DM After GDM With Immediate Postpartum Screening
NCT06457139
Diabetes Mellitus, Diabetes Mellitus, Type 2
Worcester, Massachusetts, United States
View Trial DetailsA Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
NCT07271251
Diabetes Mellitus, Diabetes Mellitus, Type 2
Koriyama-shi, Fukushima, Fukushima, Japan, Japan
View Trial Details